The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I have read somewhere that we also have a blood test/dosing tool ?
Think the DOSEMERX?
PROSTATE CANCER UK FUNDS NEW STUDY USING PARSORTIX
Research into the use of Parsortix-based CTC blood test to assess whether prostate cancer patients require prostatectomy surgery
Potential for a new standard of care in an area of high unmet medical need
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that Prostate Cancer UK has approved funding for a significant clinical study at Barts Cancer Institute, Queen Mary University of London. The study will investigate the use of the Parsortix® system to isolate circulating tumour cells (CTCs) as a predictor of future disease recurrence. Assessment of whether prostate cancer is likely to progress, if this can be done reliably, may have a major bearing on whether radical prostatectomy surgery is the most appropriate treatment choice.
The trial is being funded by a £750,000 grant from Prostate Cancer UK and will follow 200 men with localised prostate cancer over five years. The aim of the study is to see whether the presence of mesenchymal CTCs and CTC clusters in peripheral blood, assessed using the Parsortix system, can predict whether the cancer will eventually spread. The study has been designed and will be conducted by Barts Cancer Institute and is being funded by Prostate Cancer UK, both independently from ANGLE. ANGLE has agreed to provide support for the study through the provision of Parsortix instruments, cassettes and reagents.
Who knows what's happening, even the VAL BB is uncertain.
6 weeks to get it sorted (till end of June 22) Then THX exclusivity runs out, then what? The whole process starts again? I am now of the opinion that its a bonus if it happens, we have a agreement and until VAL201 goes to the next step, there is nothing to see here..
We need the news of the "large pharma" mooted some months ago, along with update on the Prostate cancer decision tool from PTTU, as well as hopefully new / renegotiated Merck DNA DDR etc
Hi Truro and others
Sorry for late reply as we have been on holiday
In reference to VAL201 I found this on the VAL website from March 2022
Suggests on or before June 2022
ith TheoremRx for the sub-license of VAL201. The LOI has been re-executed with an exclusivity period expiring before the end of June 2022.
TheoremRx reports that it continues to make good progress with its financing, however current global macro-economic events have impacted the timelines. Upon successful completion of the financing by TheoremRx, the first payments to ValiRx under the sub-license are anticipated on or before end-June 2022
Not seen for awhile a 1 buy trade.
There’s quieter than a Church Mousse and there’s Pyc.Are we still breathing and in business Mr.Millen lol?In all seriousness there seems to be a dirth of positive news dropping across the board in small cap stocks which I assume is down to the general macro climate of unease and lack of confidence to commit aka ongoing world events and political /economic challenges.Que Serra -the wait continues!
for several days now. (Rare)
spread is 4.20 / 4.40 buys coming in at in or around mid price, sells at 4.20 area.
Hopefully the new "large" contract mooted will appear and put some life back into the SP.
After been here for years, the sp never fails to surprise. Yesterday was a first, more buy volume 218k buy v a few k sells and we go down.
Discuss. :-)
Wrong login The.Italian? LOL!!
they just don't get it do they! or perhaps choose not to.
Company of market cap 4m gets a maximum 6m if a company of market cap 18m gets a minimum of 100m. Yep, makes sense that people are investing here instead of VAL on this speculation - not.
Thanks Laura - this shows the value of up-to-date research. I'm afraid I've been a little lax lately however in my defense I first bought in Oct '15 when 1K got me 1.5 Mill shares - Oh yes they ere the days!
As you say we may well get an odd chunk or two now and again. Even 10% would transform things financially but even more importantly it would give publicity and credence.
Truro
On the VAL board I says they are getting $60mln+ upfront for just one component , I would imagine PYC could get an initial milestone payment
I have added today and my husband is adding a substantial amount in his SIPP
My guess is that as Val sales start up we get a slice of each until we reach 6 Mill. Could take months but more like years but it doesn't really matter as it will be huge anyway and takes us forward into other commercial type deals in addition to consulting. Win/Win - Brucy bonus's all round!!!
Indeed, 6m or 6% of revenues for that deal. More than our market cap right now.
Thou, many questions need answering, like:: When? How much? Will we get £6m up front? Will the £6m / 6% be paid in instalments over the time of the contract? How long is the contract? sounds like the beginning of every episode of "Soap" all those years ago.
Getting closer
6 mil in the coffers
Hi Kidlington
I have read the last results in detail and that was enough information to invest my first slices, I am now reading up on the rest of the RNSs and following this board as alot of the historic RNSs I have not yet gotten round to
Correct Laura, that point has been alluded to several times here.
May i ask, an i do not wish to sound harsh etc, but did you not read the RNS's for the company for the last year or more before investing?
You did not know about Servier, which is our latest new client, and VAL which has been rumbling on for months now with their 6m or 6% capped payment for VAL201.
I have just read their March 2022 Q and A and this sounds very promising
Surely it can't be far off as we are now in May 2022
Q: Can we say how long we’ve been in discussion with the potential new big pharmaceutical client?
We’ve been in discussion with them for over 12 months, and that is common for big pharma clients. They take a long time to bring on board, but once you once you’ve got through all of their myriad procurement processes as well as the commercial negotiation around the contract then, with a following wind, they can turn out to be a client like Merck. So the opportunity is significant. It’s the sort of investment of time that, as a CEO or head of business development, you never mind making. As I said in our interims RNS, we are in in in advanced discussions with the company and we’ll say more as soon as we’re able to.
Exactly Laura! MCAP here is too low!
Many thanks
Just Read it...so looks like £6mln to come to PYC on a successful deal for VAL ?
That's more than our current value !
Will be adding more PYC
Have a read of the Mon, 15th Feb 2021 07:00 RNS
How are they connected to PYC please ?
Sorry I'm not up to date with all the news yet
Up 17% games played dropping 3% on no trades
Yes Laura, happens all the time here. 2 days is nothing, several times i have seen matched trades being bought and sold for a loss on the same day, and i am not talking about "round numbered" trades ie 25/50/100k,
They are working with Servier as per RNS in April: https://www.lse.co.uk/rns/PYC/contract-award-e5xd6dbskmk6dzw.html
Reasons to be cheerful, got start to week, drifted down on profit taking and general market sentiment, and the spread is a paltry 2.2% which is rare.